Shares of Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) have received a consensus recommendation of “Hold” from the five research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $8.00.
Several brokerages have weighed in on ANIX. HC Wainwright lowered their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, September 22nd. Wall Street Zen cut shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a report on Tuesday, October 6th.
Check Out Our Latest Analysis on ANIX
Insider Buying and Selling at Anixa Biosciences
In other Anixa Biosciences news, Director Lewis Titterton, Jr. acquired 49,036 shares of the company’s stock in a transaction dated Wednesday, September 23rd. The stock was purchased at an average price of $2.69 per share, with a total value of $131,906.84. Following the completion of the purchase, the director directly owned 1,046,003 shares in the company, valued at approximately $2,813,748.07. The trade was a 4.92% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders bought a total of 105,536 shares of company stock valued at $291,587 over the last three months. Corporate insiders own 26.40% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Jump Financial LLC purchased a new position in Anixa Biosciences in the 3rd quarter worth approximately $67,000. Marshall Wace LLP grew its holdings in Anixa Biosciences by 146.2% during the 3rd quarter. Marshall Wace LLP now owns 808,450 shares of the company’s stock valued at $2,369,000 after buying an additional 480,118 shares in the last quarter. CoreCap Advisors LLC grew its holdings in Anixa Biosciences by 19.2% during the 3rd quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock valued at $182,000 after buying an additional 10,000 shares in the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Anixa Biosciences during the second quarter valued at approximately $30,000. Finally, Corient Private Wealth LP raised its position in shares of Anixa Biosciences by 87.0% during the second quarter. Corient Private Wealth LP now owns 37,400 shares of the company’s stock valued at $105,000 after buying an additional 17,400 shares during the last quarter. 29.13% of the stock is owned by hedge funds and other institutional investors.
Anixa Biosciences Price Performance
ANIX stock opened at $2.62 on Monday. The business’s 50-day moving average price is $2.88 and its 200-day moving average price is $2.96. The stock has a market cap of $91.08 million, a P/E ratio of -8.19 and a beta of 0.47. Anixa Biosciences has a twelve month low of $2.32 and a twelve month high of $5.46.
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last released its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). On average, equities research analysts expect that Anixa Biosciences will post -0.31 earnings per share for the current fiscal year.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc. is a U.S.-based biotechnology company focused on developing cancer immunotherapies. Its research programs include a CAR T-cell therapy designed to target ovarian cancer and cancer vaccine candidates developed with research partners. The company’s ovarian cancer program uses T cells engineered to recognize follicle-stimulating hormone receptors on cancer cells and is being developed in collaboration with Moffitt Cancer Center. Anixa is also working with Cleveland Clinic on a breast cancer vaccine program intended to stimulate an immune response against cancer-related targets.
Featured Stories
- Five stocks we like better than Anixa Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
